Novo Nordisk A/S’s (NVO) “Sell” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Novo Nordisk A/S (NYSE:NVO)‘s stock had its “sell” rating restated by Deutsche Bank Aktiengesellschaft in a note issued to investors on Tuesday.

Several other equities analysts have also recently commented on the stock. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Weiss Ratings upgraded shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Three research analysts have rated the stock with a Buy rating, seventeen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $61.94.

Novo Nordisk A/S Price Performance

NVO stock traded up $0.24 on Tuesday, hitting $38.55. 11,776,206 shares of the company’s stock traded hands, compared to its average volume of 17,066,984. The stock has a market cap of $172.11 billion, a price-to-earnings ratio of 9.42, a P/E/G ratio of 1.27 and a beta of 0.74. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The stock has a fifty day moving average of $45.28 and a 200-day moving average of $43.86.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. On average, analysts forecast that Novo Nordisk A/S will post 3.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVO. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Novo Nordisk A/S by 2,414.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after acquiring an additional 286,034 shares in the last quarter. Trust Co. of Vermont bought a new position in Novo Nordisk A/S during the 2nd quarter worth about $1,250,000. Burkett Asset Management Ltd acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $1,823,000. Myriad Asset Management Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $1,846,000. Finally, Pine Valley Investments Ltd Liability Co acquired a new position in shares of Novo Nordisk A/S during the second quarter worth about $2,324,000. Institutional investors own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo signed an exclusive licensing agreement with Hengrui Pharma for HRS-1596, a phase 1-ready, once-weekly oral GLP-1/GIP drug candidate. The deal is worth up to $2.6 billion, including $300 million upfront, and expands Novo’s pipeline of oral obesity treatments and potential alternatives to daily pills. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: A real-world analysis presented at a medical meeting found that patients switching from Wegovy or Eli Lilly’s Zepbound injections to Novo’s daily Wegovy pill lost about 4% of their body weight over three months. The data supports demand for a more convenient oral option and helps Novo defend its position in the obesity market. People switching to Novo’s Wegovy pill from obesity injections kept losing weight in real-world study
• Positive Sentiment: Novo reported real-world evidence suggesting patients who increased Ozempic to 2 mg had a 6% lower risk of major cardiovascular events than patients who switched to Lilly’s Mounjaro. While observational rather than a head-to-head clinical trial, the finding strengthens Ozempic’s differentiation. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro
• Positive Sentiment: Recent CagriSema phase 3 data showed 12.4% weight loss after 60 weeks in a type 2 diabetes study, improving confidence in another late-stage obesity asset. Novo is also pursuing longer-acting delivery technology through its Nanexa collaboration. Novo Nordisk Just Beat Lilly in a Trial
• Neutral Sentiment: Novo’s share-repurchase program remains in progress, with a broader authorization of up to DKK 15 billion over 12 months. Buybacks may provide technical support, but they do not resolve the company’s growth and competitive challenges. Novo Nordisk share repurchase programme
• Negative Sentiment: Investors remain concerned about an “uninspiring” growth outlook and competition from Lilly. Lilly has claimed its oral obesity treatment, Foundayo, delivers greater weight loss and better blood-sugar control than higher-dose Ozempic, while some analysts continue to rate NVO only “Hold.” Novo Nordisk Gives Uninspiring Outlook

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.